Cancer has emerged as a significant global public health concern, imposing a substantial and ever-increasing socioeconomic burden. The gut microbiota has been established as a critical component in regulating host immunomodulation, maintaining cancer immune homeostasis, and modulating the tumor microenvironment. Recolony is pioneering a groundbreaking approach to cancer treatment by harnessing the potential of the human microbiota. They have uncovered a specific mechanism, by which the gut microbiota activates the immune system, revealing a novel target for cancer immunotherapy. Through in-depth analysis of the host-microbiota interactions, they have identified a specific bacterial metabolite that exhibits potent anti-tumor properties. This metabolite has been shown to activate the immune system by binding to a receptor on tumor-residing macrophages, stimulating a pro-inflammatory response that combats cancer. Treatment with the bacterial metabolite showed efficacy in different mouse solid tumor models, validating the target receptor for multiple cancer entities. Building on this discovery, Recolony is developing a novel small molecule immunotherapy that mimics the natural anti-cancer effects of microbial-derived metabolites, but with enhanced efficacy. Their therapy is designed to optimize treatment outcomes for late-stage cancer patients, offering a promising new hope for those affected by this devastating disease.
Zurich, CH
We are celebrating our second anniversary! 🥳
Two years of growth, innovation, and teamwork! We're thrilled to celebrate our 2nd anniversary at Recolony! To mark this milestone, we're bringing the team together for a fun-filled day of great food, drinks, and VR adventures! Here's to many more years of success and many more reasons to celebrate together!
Only 10 days left to make your voice heard! 📢 We're thrilled to be part of the TOP 100 Public Voting 2024 and we need your support! If you haven't already, please take a minute to vote for Recolony by following this link https://lnkd.in/dusNNiz4 . Your vote matters and we're grateful to those who have already cast their ballot for us. Let's make it happen! #TOP100SSU #biotech #innovation #cancertherapy
Vote for Recolony for the Top100 Swiss startups 2024 Thank you for your support! https://lnkd.in/eaqmT6RU #TOP100SSU
Recolony AG hat dies direkt geteilt
"My name is Sarah Basore, and I was diagnosed with stage IV colon cancer in May 2023 at the age of 21. I had traceable symptoms for about a year leading up to being diagnosed. I was in the midst of college and running track, so I was able to dismiss the symptoms as being IBS, lactose intolerance, etc. I thought all my fatigue was from the strenuous training I was doing every day. I pushed through 3-4 episodes that I should have gone to the ER for in hindsight. In February, I started noticing blood in my stool, and that is what prompted me to go to a gastroenterologist. I took photos and logged symptoms, and it was enough to convince my G.I. doctor to recommend a colonoscopy. In the colonoscopy, they found a tumor, and a subsequent CT scan found lesions on my liver. I endured 12 rounds of heavy-duty chemo, with #12 landing me in the hospital for over 10 days. That hospital stay was my lowest moment physically - I was extremely sick with extreme chemo toxicity and dehydration. The hospital stay did allow me to get healthy again and healthy enough for surgery in January. My colon and liver were resected with clear margins, and I am now doing chemo again before I scan at the end of April to see if it's safe to go off chemo. I want to reach as many people as possible to encourage them to listen to their bodies and to advocate for themselves. I started sharing publicly on social media and even started a podcast with my friend Jay called "I Can't Die I'm Busy." It's an homage to Jay's best friend, who passed away from DIPG. I am now in a healthy place with my mental health and want to spread awareness about the epidemic of young people being diagnosed with late-stage colorectal cancer." - Sarah Basore
Recolony AG hat dies direkt geteilt
AACR conference is one of the biggest cancer research conferences worldwide! So many experienced and passionate researchers aspiring to find the treatment of tomorrow! Extremly proud that I get a chance to be part of #AACR2024 ! Meet me today at my poster: section 2, board 10! #Recolony AG, #WyssZurich, #Innovation, #Microbiome, #AACR2024
Our CEO, Ana Montalban-Arques, was recently featured on the Swisspreneur podcast, where she discussed our bacteria-based cancer therapy and shared her personal experiences as an entrepreneur. You can check out the episode on Spotify. https://lnkd.in/eAzKgsq2
Recolony AG hat dies direkt geteilt
Attention regulatory colleagues! 🚨 Ready for a new career adventure? I'm resharing this unique regulatory role at Zürich-based startup Recolony AG: https://lnkd.in/dPuu-YCq For more information reach out to Ana Montalban-Arques. #RegulatoryOpportunity #Recolony #JobOpening
Recolony AG hat dies direkt geteilt
💡 Erfunden an der UZH: Bakterien gegen Krebs. Das UZH-Start-up Recolony AG arbeitet an einer revolutionären Krebstherapie. Sie basiert auf Darmbakterien, die Krebspatient:innen verabreicht werden. «Bei Versuchen mit Mäusen wurden die Tumoren kleiner oder verschwanden sogar ganz», erklärt die Gründerin von Recolony Ana Montalban-Arques. Jetzt entwickelt das Team der Molekularbiologin mit diesem Wissen eine Krebstherapie für Menschen. Konkret geht es darum, den Darm von Krebspatient:innen, wieder mit spezifischen Darmbakterien zu besiedeln, denn diese nehmen bei einer Erkrankung ab. «Diese Bakterien lösen eine Immunantwort gegen die Krebszellen aus», sagt Montalban-Arques. Die Therapie ist effektiv in Modellen für Darm-, Haut-, Brust- und Lungenkrebs und kann möglicherweise auch für weitere Krebsarten eingesetzt werden. Der Vorteil gegenüber herkömmlichen Chemotherapien liegt auf der Hand: Die körpereigenen Bakterien bekämpfen den Krebs, ohne andere Körperzellen zu zerstören. Im Moment geht Montalban-Arques davon aus, dass die Bakterientherapie in Kombination mit Chemotherapien eingesetzt wird. «Ziel ist jedoch, auf die Chemotherapie verzichten zu können.» Der Terminplan ist ambitioniert: 2025 starten die klinischen Studien, 2031 soll die Therapie auf den Markt kommen. 👉 www.recolony.ch Aus dem UZH Magazin 4/23, Text: Thomas Gull #Innovation #Research #Startup Universität Zürich | University of Zurich UZH Innovation Hub
Recolony AG hat dies direkt geteilt
We are thrilled to present at Biotech Showcase 2024, January 8–10, 2024 in San Francisco. Join me to meet one-to-one! https://lnkd.in/dSfg6ZQz . Informa Connect
Recolony AG hat dies direkt geteilt
Merry Christmas from the Recolony team! This year has been one of remarkable growth in our team, marked by significant progress in the development of our groundbreaking microbiome-based cancer therapy. May the New Year bring us continued success, unwavering resilience, and endless opportunities to create a brighter future. Thank you to all out supporters and partners for being a part of the Recolony family. We wish you a joyous and prosperous holiday season!